Pharmaceutical Business


Information provision activities

New drugs are delivered to patients after passing a long process that includes basic research, clinical studies and review by the government for regulatory approvals. Even after drug products are launched and used by a large number of patients, safety and efficacy are continually checked resulting in safe and secure, useful pharmaceuticals. It is only after proper usage has been established based on safety and efficacy information that the pharmaceuticals can fulfill their desired function of contributing effectively to human health requirements.
At Sumitomo Dainippon Pharma, we collect and share safety information and provide the requisite and specialized information to medical professionals via our MRs (Medical Representatives) and multiple media outlets. Our aim is to earn greater confidence among medical professionals and to contribute to the betterment of healthcare and fuller lives of patients through daily information provision activities.

Focus areas for the Japan business

In Japan, we collect and provide professional information primarily in the Psychiatry & Neurology, Diabetes, and Specialty areas.
In the Psychiatry & Neurology area, we have therapeutic drugs for Parkinson's disease and schizophrenia and we aim to contribute to the treatment of psychiatric and neurological diseases as a medical partner.
In the Diabetes area, we offer several drugs with different mechanisms of action and respond to a wide range of medical needs. Furthermore, in the Specialty area (an area with high unmet medical needs in which intensive specialization is required), we contribute to the medical care in such fields as rare diseases, hematologic disorders, and liver diseases.

Product lineup

Major pharmaceutical productsTherapeutic indication
TRERIEF® Therapeutic agent for Parkinson's disease
LATUDA® Atypical antipsychotic
LONASEN® Tape Atypical antipsychotic
EFFEXOR® Therapeutic agent for depression
Trulicity® Therapeutic agent for type 2 Diabetes
Equa® Therapeutic agent for type 2 Diabetes
EquMet® Therapeutic agent for type 2 Diabetes
SUREPOST® Therapeutic agent for type 2 Diabetes
METGLUCO® Therapeutic agent for type 2 Diabetes
REPLAGAL® Therapeutic agent for Anderson-Fabry disease drug
AmBisome® Therapeutic agent for systemic fungal infection
REMITCH® Therapeutic agent for pruritus

Research and Development

The Group remains committed to research and development by taking every available opportunity to assimilate cutting-edge technologies through combinations of a wide variety of avenues, including in-house research, technology in-licensing, and joint research with biotech companies and academia. The aim is continuous discoveries of excellent pharmaceutical products in the focus areas; Psychiatry & Neurology, Oncology, and Regenerative Medicine and Cell Therapy. In a bid to contribute to global health, the Group is also working on the Infectious Diseases area. Furthermore, with the aim of providing new solutions to social issues in healthcare areas other than pharmaceuticals, we are working toward launching frontier businesses.

Psychiatry and Neurology

The Company is leveraging its core competencies to forge ahead with drug discovery research based on its proprietary drug discovery platforms established by constantly incorporating cutting-edge technologies. Every effort is being made to boost the success rate of R&D by applying a wealth of knowledge, gained from clinical study data of in-house products, to translational research and by selecting drug discovery targets and biomarkers through the use of big data, such as genome information and image pictures. The Company aims to optimize treatments for psychiatric disorders (schizophrenia, bipolar depression, and neurological symptoms) through drug discovery research based on neural circuit pathology. For neurological disorders (dementia, Parkinson's disease, and rare diseases), The Company aims to develop innovative disease-modifying treatments through drug discovery based on molecular pathophysiology.
In the development stages, the Company is working closely with its U.S. subsidiaries under the global clinical development framework to efficiently promote clinical development according to strategic development planning, aiming at quickly obtaining regulatory approvals.


The Group aims to create innovative new drugs by conducting research projects that focus on cell-cell interaction in the tumor microenvironment as part of its efforts to work on unique seeds and themes. Moreover, the Company will strive for innovative technologies utilizing external collaboration and promote drug discovery and development leveraging big data and digital technologies. By accelerating collaborative R&D efforts, integrating its subsidiaries in North America and external parties, the Group aims to swiftly move the outcomes of the projects to clinical trials through seamless collaboration between research and development.
In the development stages, the Group is working proactively on early-stage clinical development, while steadily advancing development of late-stage products.

Regenerative medicine / Cell therapy

The Company is promoting multiple R&D projects with a view toward quickly commercializing regenerative medicine and cell therapy by developing a unique growth model where we pursue advanced industrialization/manufacturing technologies and cutting-edge science through the open innovation strategy. The Company steadily promoting research projects mainly in Neurology and Ophthalmology seeking early commercialization. The Company also setting our sights on next-generation regenerative medicine, including the regeneration of organs, and aim for global expansion (Japan, the U.S., and Asia). First, we will aim to realize financial contributions mainly in Japan and the U.S. during the next MTBP period (fiscal 2023-2027).

Infectious Diseases

Through joint research with academic institutions, the Company is conducting drug discovery research of treatments for antimicrobial-resistant bacterial infections, and of malaria vaccines and universal influenza vaccines based on its adjuvant technologies.

Frontier businesses

The Company will build a business platform consisting of key technologies (including ICT and engineering) and networks (including partnership with startups and venture capitals) in areas where we can create synergies with our pharmaceutical business to respond to future needs for healthcare. The Company will work for commercialization during the current MTBP period and aspire to establish frontier business as a growth engine during the next MTBP period (fiscal 2023-2027).
・Frontier Business Site

Pharmaceuticals production

We have built a stable supply structure for our products, which are manufactured mainly at our own plants in Japan and also in collaboration with partners in Japan and other countries. Our plants have worked hard to increase the precision of their production plans by strengthening collaboration with the Sales & Marketing Division, the International Business Management Department, overseas subsidiaries, and business partners. We have also made proactive efforts such as double sourcing of active pharmaceutical ingredients and optimizing the supply chains regarding the formulation and packaging of products. To further strengthen our competitiveness, we continuously work on cost reduction activities, as well as actively striving to increase productivity in our plants, such as by reducing lead times.

Suzuka Plant

The Suzuka Plant is Sumitomo Dainippon Pharma's core formulation plant, equipped with integrated pharmaceutical manufacturing facilities capable of a full range of operations from the production of active pharmaceutical ingredients to the formulation and packaging of products. It includes a state-of-the-art solid dosage formulation facility fully compliant with cGMP (the latest U.S. GMP) and supplies products globally.

Oita Plant

The Oita Plant is Sumitomo Dainippon Pharma's principal facility for the production of active pharmaceutical ingredients and its equipment is cGMP-compliant. It operates 24 hours a day, 365 days a year to ensure stable production of active pharmaceutical ingredients.


Under the umbrella of Sumitomo Dainippon Pharma America, Inc., a wholly owned holding company, Sunovion Pharmaceuticals Inc. is engaged in manufacturing and sales of pharmaceuticals; Sumitomo Dainippon Pharma Oncology, Inc. in R&D activities and related marketing preparations in the oncology area.
Under Sumitovant Biopharma, a holding company established in December 2019, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences, all consolidated subsidiaries of Sumitomo Dainippon Pharma, are engaging in pharmaceutical R&D.

Sunovion Pharmaceuticals Inc. Product lineup

Major pharmaceutical productsTherapeutic indication
LATUDA® Atypical antipsychotic
APTIOM® Antiepileptic
KYNMOBI OFF episodes associated with Parkinson's disease
BROVANA® Therapeutic agent for COPD
LONHALA® MAGNAIR® Therapeutic agent for COPD


Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. is engaged in manufacturing (subdivided packaging) and sales of pharmaceuticals.

Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. Product lineup

Major pharmaceutical productsTherapeutic indication
MEPEM® (Brand name in Japan: MEROPEN®) Carbapenem antibiotic
ALMARL® (Brand name in Japan: Arotinolol Hydrochloride) Therapeutic agent for hypertension, angina pectoris and arrhythmia
LONASEN® Atypical antipsychotic
LATUDA® Atypical antipsychotic